NHP Models of Diabetes

A unique resource of spontaneously diabetic NHPs


Spontaneously Diabetic NHPs or Diet Induced?

NHP models that spontaneously develop Type 2 diabetes (T2D) show all of the characteristics of T2D patients at different stages of the progressive disease. They are by far the most predictive animal model system for human metabolic syndrome, including diabetes.

Using animal models with such a close resemblance to human disease results in the most reliable preclinical data to inform on clinical trials and allows the investigation of the mechanisms underlying human T2D.

Before moving your agent to successful human clinical trials, NHP models provide invaluable data on:

  • Efficacy
  • PK/PD relationship
  • Biomarkers
  • Adverse effects

CrownBio provides the world’s largest collection of well-characterized naturally diabetic NHPs including both cynomolgus and rhesus monkeys, which mirror every aspect of the human disease including disease progression, obesity, and complications such as nephropathy, neuropathy, and dyslipidemia, making them the ideal system for preclinical investigation of next generation antidiabetic agents.

Metformin Treatment Reduces Blood Glucose and HbA1c Levels in Diabetic NHPs

The Premier Translational Platform for All Stages of Diabetes

Our experienced scientific team can perform a wide range of in vivo and in vitro assays, to evaluate the efficacy and PK/PD effects of your compound.

Our in vivo pharmacology capabilities include the evaluation of:

  • Compound’s pharmacological properties (dose-response, efficacy, and PK)
  • Blood chemistry (lipid profile, free fatty acids, etc.)
  • Body weight/body composition (lean and fat mass)
  • Food and liquid consumption
  • Fasting glucose and insulin index
  • Glucose disposal rate (glucose tolerance test, GTT)
  • Insulin sensitivity or resistance (insulin tolerance test, ITT)
  • Hepatic glucose genesis (pyruvate tolerance test, PTT)
  • Incretin response (meal tolerance test, MTT)
  • Islet function (graded glucose infusion, GGI)
  • Glucose disposition and insulin sensitivity (glucose and insulin clamps)
  • Gastric empty rate
  • Renal function (urine volume, protein, glucose, creatinine excretion, GFR)
  • Continuous glucose monitoring (CGM) by telemetry in rodents and NHPs
  • Safety pharmacology: potential side effects
  • Biopsy/autopsy, histopathology
  • Heart or liver function (noninvasive sonography)

At CrownBio we routinely run in vitro assays to evaluate glucose stimulated insulin secretion on the following models:

  • INS-1 cells
  • isolated primary islets from different species
  • immortalized human islet cells
CVMD Webinar